Harnessing a Secret Killer: Inflammation and Its Ultimate Resolution
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 2151
Special Issue Editor
Interests: cancer therapeutics; nitric oxide; hydrogen sulfide; cell signaling; resolution
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
It has long been known from the 11th century “The Canon of Medicine,” a historical encyclopedia of medical books, that inflammation is not all bad and can be good—“pus bonum ert laudiable” (good and laudable pus). While an acute inflammatory response in the human body is protective from tissue injury via wound healing and regeneration such as after surgery or in response to infections, microorganisms, and viruses, unresolved/uncontrolled systemic inflammation is a prominent component of many diseases, including arthritis, periodontal disease, inflammatory bowel disease, cardiovascular disease, heart arrythmias, neurodegenerative diseases (e.g. Alzheimer’s and Parkinson’s), asthma, metabolic syndromes (e.g., obesity), diabetes, autoimmune disease and cancer.
A paradigm shift is emerging in our understanding of the pathogenesis of inflammation; while previously thought to result from the persistent activation of inflammatory signals, it is now appreciated that the loss of pro-resolving mechanisms plays a critical role. Differentiating between suppression and resolution of inflammation driven by pro-resolution lipid autacoid mediators is critical in treating various inflammatory diseases.
A new direction of inflammation research has emerged with the discovery of the autacoid superfamily of specialized pro-resolving lipid mediators (SPMs), including resolvins, maresins, protectins, and lipoxins. These SPMs have potent inflammation clearing activity without being immunosuppressive. The resolution of inflammation is now appreciated to be an active process that is regulated by these SPMs, which are endogenously produced in multiple tissues throughout the human body.
IJMS invites you to submit by 31 March 2023 a manuscript for inclusion in this Special Issue aimed to explore the ramifications and potential therapeutics associated with SPMs. Submission format may be a review or original research.
Prof. Dr. Khosrow Kashfi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inflammation
- cancer
- heart disease
- neurodegenerative diseases
- diabetes
- arthritis
- periodontal disease
- inflammatory bowel disease
- aspirin
- nitric oxide
- hydrogen sulfide
- carbon monoxide
- omega-3 polyunsaturated fatty acids
- eicosapentaenoic acid (EPA)
- docosahexaenoic acid (DHA)
- resolvins
- SPMs
